The median forecasts in this calendar come from surveys of economists conducted by Dow Jones Newswires and The Wall Street Journal. All statistics in this calendar are in expressed in nominal ...

Some 8.5 million visitors are expected to visit the resort, on the site of a former brickworks near Bedford, in its first year. Lafayette, April 08, 2025 (GLOBE NEWSWIRE) -- Lafayette, Colorado ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

We list the best calendar apps, to make it simple and easy to better organize your schedule. Whether you're running your own business or an employee, chances are there aren't enough hours in the ...

It’s one of those interesting moments in time.” Google launched Vertex AI way back in 2021 as a platform for developers to build machine learning services in the cloud. That was, of course ...

Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 have been able to come off insulin altogether within a year, raising the prospect of a life without ...

Stifel Nicolaus analyst Brad Reback maintained a Hold rating on Vertex (VERX – Research Report) today and set a price target of $31.00. The company’s shares closed yesterday at $36.45.

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to trigger sufficient levels of insulin production in a phase 1/2 trial.

There’s a lot to be optimistic about in the Technology sector as 2 analysts just weighed in on Vertex (VERX – Research Report) and AppLovin (APP – Research Report) with bullish sentiments.

Vertex holds a dominant position in the cystic franchise (“CF”) market. Its CF sales continue to grow, driven by higher sales of Trikafta/Kaftrio in younger age groups. Vertex’s CF product ...